New antiretroviral launched in the UK
Rilpivirine, a?new non-nucleoside reverse transcriptase inhibitor, has been launched in the UK for the management of HIV-1 infection in treatment-naive patients.
It will be available as a single-ingredient preparation (Edurant) and in a triple-combination tablet with emtricitabine and tenofovir (Eviplera). Rilpivirine must be taken with food and has several clinically significant drug interactions.
Citation: Clinical Pharmacist URI: 11090936
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now